Mineralys Therapeutics presents new Lorundrostat Launch-HTN data

New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of =10 mmHg systolic blood pressure reduction - - In the Explore-OSA trial in participants with obstructive sleep apnea, lorundrostat 50 mg taken once daily in the evening achieved clinically meaningful reductions in morning systolic blood pressure with no measurable change in apnea-hypopnea indices - RADNOR, Pa., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the presentation of a new analysis from its pivotal Phase 3 Launch-HTN trial, showing that at Week 12, 46% of lorundrostat-treated participants achieved the AHA/ACC Guideline recommended office systolic blood pressure (SBP) target of <130 mmHg. These results were presented at the American Heart Association Hypertension Scientific Sessions 2026 (AHA-HTN), taking place October 7-11 in Arlington, VA. "Hypertension remains the most important risk factor for cardiovascular diseases, as blood pressure control rates remain poor. Participants in Launch-HTN had uncontrolled or treatment-resistant hypertension, despite being treated with two to five antihypertensive therapies. In this new analysis, nearly half of the lorundrostat-treated participants achieved a guideline-recommended SBP below 130 mmHg," said Manish Saxena, MBBS, principal investigator on the study and Deputy Clinical Co-Director of Queen Mary University of London's William Harvey Heart Centre, and Hypertension Specialist at Barts Health NHS Trust. "In addition, 70% of lorundrostat-treated participants achieved an SBP reduction of 10 mmHg or more, a level that, if sustained in the long term, is associated with a 20% reduction in the risk of a cardiovascular event. The results of the analysis reinforce the potential of lorundrostat to deliver clinically meaningful reductions in blood pressure in patients with difficult-to-treat hypertension." In a separate oral presentation, the final results of the Phase 2 Explore-OSA trial of lorundrostat in overweight or obese adults with moderate-to-severe OSA and hypertension were featured. Participants receiving lorundrostat 50 mg once daily in the evening achieved clinically meaningful reductions in morning SBP of 11.1 mmHg at Week 4 (p<0.0001), compared with 1.0 mmHg reduction for participants receiving placebo (p=NS), although no measurable change in apnea-hypopnea indices were observed with lorundrostat. In the study, lorundrostat exhibited a favorable safety and tolerability profile, and there was no evidence of significant safety events, including hyperkalemia (high serum potas